rare diseases

Economy China bans export of Korean goods containing its rare earth metals to US

The Chinese government has warned South Korean companies of retributions for exporting any product containing its critical metals to US military con...

Bio & Pharma Celltrion wins Australian approval for eye, bone disease biosimilars

Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...

Korean Investors Samsung to invest $10 million in US-based C2N Diagnostics

Samsung Group companies will jointly invest $10 million in C2N Diagnostics LLC, a U.S.-based company specializing in blood-based Alzheimer’s d...

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Batteries SK Ecoplant, BMW team up for battery recycling

SK Ecoplant Co., a South Korean construction engineering and waste management company under SK Group, partnered with German luxury carmaker BMW to...

Bio & Pharma Celltrion obtains approval of Steqeyma from FDA

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Bio & Pharma Celltrion releases Steqeyma in Europe

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

Bio & Pharma Celltrion's Zymfentra gets 90% distribution channel in US

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

Bio & Pharma IMBiologics transfers autoimmune disease drug tech to Huadong Pharma

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

Bio & Pharma Costco sells Celltrion's Yuflyma Low WAC in US

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

Bio & Pharma Celltrion gets approval of Steqeyma in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

North Korea A North Korean Diplomat Managed a Rare Defection: A Flight Out of Cuba

SEOUL—A North Korean diplomat posted in Cuba defected to South Korea with his family late last year, officials said this week, a rare esc...

Electric vehicles Korea Eximbank to provide $150 mn PF to Australia

The Export-Import Bank of Korea (Eximbank) announced on Tuesday that it will provide $150 million in project financing (PF) for developing a rare ea...

Electric vehicles Hyundai Motor, Kia to develop alternative to rare earth materials

Hyundai Motor Co. and Kia Corp. have partnered with South Korea's universities to secure materials for vehicle electrification components.Hyundai Mo...

Business & Politics SoftBank to buy part of Naver's Line stake by July: CEO Miyakawa

TOKYO – SoftBank Corp., which runs LY Corp., the operator of the popular mobile messenger app Line in Japan, said on Thursday it is in talks w...

Bio & Pharma Celltrion to supply Remsima, Herzuma to Peru

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

Bio & Pharma Samsung Bioepis gets OK to sell Stelara biosimilar in Europe

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...

Bio & Pharma Celltrion releases Remsima SC in Denmark

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

Bio & Pharma Samsung begins new drug development for rare diseases

Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...

Bio & Pharma Reversing age possible in a decade: Harvard Prof. David Sinclair

Humans will be able to control biological age and reverse their age in 10 years with advancements in medical science and live up to around 120, abou...

Bio & Pharma Celltrion'a autoimmune disease drug Zymfentra makes US debut

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

Bio & Pharma Celltrion ships initial supply of Zymfentra to US

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

Artificial intelligence Kakao Brain releases medical GenAI tech for free

Kakao Brain, an artificial intelligence (AI) R&D subsidiary of South Korea's Kakao Corp., announced on Tuesday that it has uploaded the Labeler ...

Bio & Pharma Celltrion to supply Remsima SC, Yuflyma to Norway

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...

Bio & Pharma Kakao launches AI-based blood sugar management solution

South Korea’s Kakao Healthcare Corp. has introduced an artificial intelligence-based blood sugar management solution targeting the global digi...

Korean chipmakers POSCO to foster rare gas business with Zhongtai Cryogenic

POSCO Holdings Inc. will build a highly purified rare gas-producing joint venture in South Korea with Zhongtai Cryogenic Technology Corp. from China...

Bio & Pharma ToolGen gets FDA approval for TGT-001 as ODD

South Korean genome editing developer ToolGen Inc. announced on Monday that its application for orphan drug designation (ODD) of the gene correction...

Bio & Pharma SK C&C to promote AI healthcare for brain diseases

South Korea's SK C&C announced on Thursday that it signed a strategic business agreement with Neurophet, a cloud-based AI platform for brain ima...

Bio & Pharma Dong-A ST, UMass to jointly research for gene therapy

South Korea's Dong-A ST announced on Friday it has signed a joint research agreement with the University of Massachusetts (UMass) Chan Medical Schoo...

Bio & Pharma Naver-invested ichrogene enters Thai market

South Korea's digital healthcare startup ichrogene, with investment from Naver D2 Startup Factory (D2SF), entered into Thai market. Naver Corp....